



COPY OF PAPERS
ORIGINALLY FILED

Attorney Docket No.: 6210.200-US

245
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Andersen et al.

Application No.: Continuation of 10/002,826 Group Art Unit: To be assigned

Filed: November 30, 2001

Examiner: To be assigned

Confirmation No.: 7631

For: Production of Heterologous Polypeptides in Yeast

**PRELIMINARY AMENDMENT AND RESPONSE TO NOTICE TO
TO FILE MISSING PARTS NONPROVISIONAL APPLICATION**

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to File Missing Parts of Nonprovisional Application dated March 27, 2002, please amend the above-captioned application as follows:

IN THE SPECIFICATION:

At page 12, lines 31-36, and page 13, lines 1-2, please delete:

“Oligonucleotides were designed that allowed PCR amplification of a DNA fragment encoding amino acids 23 to 265 of Sf-IBP furnished with an N-terminal extension having the amino acid sequence EEAEPK. Using a combination of PCR and overlap PCR, followed by isolation and cloning by standard methods (Horton et al., Gene 77:61-68, 1989, Sambrook et al., 1989) an expression vector pEA263 containing an expression cassette encoding SP-leader-KR-Ext-Sf-IBP was obtained. The EcoRI/NheI fragment from plasmid pEA263 containing the expression cassette was ligated to the *Ncol/NheI* and the *Ncol/EcoRI* fragment (containing the CIT1 promoter) from pEA268 resulting in the final plasmid pEA286.”

and insert

--Oligonucleotides were designed that allowed PCR amplification of a DNA fragment encoding amino acids 23 to 265 of Sf-IBP furnished with an N-terminal extension having the amino acid

sequence EEAEPK SEQ ID NO. 5. Using a combination of PCR and overlap PCR, followed by isolation and cloning by standard methods (Horton et al., Gene 77:61-68, 1989, Sambrook et al., 1989) an expression vector pEA263 containing an expression cassette encoding SP-leader-KR-Ext-Sf-IBP was obtained. The EcoRI/NheI fragment from plasmid pEA263 containing the expression cassette was ligated to the *Ncol/NheI* and the *Ncol/EcoRI* fragment (containing the CIT1 promoter) from pEA268 resulting in the final plasmid pEA286.--

REMARKS


The specification has been amended to provide SEQ ID NO 5 on page 12-13. This submission contains no new matter.

The content of the paper entitled "SEQUENCE LISTING" and of the accompanying identically labeled diskette, both of which were submitted on November 30, 2001, is the same. Furthermore, the information contained in the "SEQUENCE LISTING" document and the ASCII-encoded file is identical to the information in the specification as filed. No new matter was added.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: May 28, 2002



Reza Green, Reg. No. 38,475
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123



23650

PATENT TRADEMARK OFFICE